by April Breyer Menon | Feb 1, 2021
As part of the “Consolidated Appropriations Act, 2021,” a COVID-19 relief and spending bill, 42 U.S.C. § 262(k) was amended to include new provisions for the FDA’s Database of Licensed Biological Products (“Purple Book”). According to the new legislation, within 180...
by April Breyer Menon | Jan 3, 2021
Venable Fizpatrick partner Ha Kung Wong spoke with Law360 for an article analyzing the patent cases to watch in 2021, including U.S. v. Arthrex, which involves the constitutionality of how administrative patent law judges who preside over inter partes review (IPR) and...
by April Breyer Menon | Dec 30, 2020
The Center for Biosimilars’ “Not So Different” podcast “Biosimilar Law Experts Discuss Potential Bills and Chances for Passage” featuring Venable Fizpatrick’s Ha Kung Wong and April Breyer Menon, was one of the series’...
by April Breyer Menon | Dec 29, 2020
Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article discussing what to expect for biosimilars in 2021, including the potential for the first authorized biologics, and the Arthrex v. Smith & Nephew case pending at the...
by April Breyer Menon | Dec 28, 2020
Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article reflecting on the biosimilar market in 2020 and what to expect in 2021, particularly with respect to the BPCIA, which is under review at the Supreme Court. The article by The...
by April Breyer Menon | Nov 30, 2020
Venable has released its annual statistical report on AIA trials before the USPTO’s Patent Trial and Appeal Board, including stats for IPRs, PGRs, and CBMs. The in-depth study analyzes the types of arguments that succeed more often than others and the trends...